Nanoparticles (NPs) have attracted considerable attention in various fields, such as
cosmetics, the food industry, material design, and nanomedicine. In particular, the fast …

Much progress has been made in targeting CD47 for cancer immunotherapy in solid tumors
(ST) and hematological malignancies. We summarized the CD47-related clinical research …

Cancer immunotherapies targeting adaptive immune checkpoints have substantially
improved patient outcomes across multiple metastatic and treatment-refractory cancer types …

Red blood cells (RBCs) and RBC membrane-derived nanoparticles have been historically
developed as bioinspired drug delivery systems to combat the issues of premature …

Microglia regulate synaptic circuit remodeling and phagocytose synaptic material in the
healthy brain; however, the mechanisms directing microglia to engulf specific synapses and …

Immune checkpoint inhibitors, including those targeting CTLA‐4/B7 and the PD‐1/PD‐L1
inhibitory pathways, are now available for clinical use in cancer patients, with other …

CD47 acts as a" don't eat me" signal that protects cells from phagocytosis by binding and
activating its receptor SIPRA on macrophages. CD47 suppresses multiple different pro …

The success of cancer immunotherapy has generated tremendous interest in identifying new
immunotherapeutic targets. To date, the majority of therapies have focussed on stimulating …

CD47, a “don't eat me” signal for phagocytic cells, is expressed on the surface of all human
solid tumor cells. Analysis of patient tumor and matched adjacent normal (nontumor) tissue …

The adaptive immune checkpoints such as PD-1 (programmed death-1)/PD-L1
(programmed death-ligand 1) play an important role in cancer immunotherapy, whereas …